Overview
Alcid develops AI-based bioinformatics tools to analyse medical images and automate diagnosis of bladder, breast and cervical cancer, as well as respiratory diseases. The company offers second-opinion consultations and conducts tests, including HER2/neu gene testing.
Financials
Revenue history (in k)
Filing timeliness
4 of 6 financial statements were filed late (the longest delay 555 days for 2020).
- 202515/07/2026
- 202414/07/2025
- 202330/09/2024
- 202230/09/2024
- 202123/04/2023
- 202023/04/2023
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Development of a bioinformatics tool automating breast cancer diagnosis
Development of a bioinformatics tool automating breast cancer diagnosis
Development of a bioinformatics tool automating breast cancer diagnosis
Development of a bioinformatics tool automating breast cancer diagnosis
Development of a bioinformatics tool automating breast cancer diagnosis
Development of a bioinformatics tool automating breast cancer diagnosis
Industry
Offer
- Diagnostic software
- Medical image analysis
- Second-opinion consultations
- Genetic tests
- Oncology panels
- Bioinformatics tools
Website technology
- Website
- WordPress
Authorized Representatives
Manner of representation
Two members acting jointly, or one in the case of a one-person management board.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Artur Paweł Olszewskiage 54 | 115 | $1,553.21 | 95.8333% |
Others | 5 | $67.53 | 4.1667% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2017-02-08.
11 1160 2202 0000 0003 0730 4172
Debt
No entries in the National Debtors Register (KRZ).
Public aid
13 public aid cases recorded, with a total value of $6,034,734.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 3, 2025 | Aid for projects awarded a Seal of Excellence quality label | –– | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Sep 2, 2024 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Feb 20, 2023 | Aid for research and development projects: industrial research | –– | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
5 projects co-financed from European Funds recorded, with total EU co-financing of $5,335,305.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-10-21 | A bioinformatics tool for automating the diagnosis of respiratory diseases using 3D cell images and Deep Learning tools | $1.8M$1,825,381 | European Funds for a Modern Economy | |
| 2022-12-15 | Development of a bioinformatics tool to automate the diagnosis of bladder cancer. | $1.5M$1,494,888 | Operational Programme Smart Growth | |
| 2022-04-01 | Preparation of a complete application package for the EIC Accelerator competition under the third pillar of the Horyzont Europa programme | $35,999$35,999 | Operational Programme Smart Growth |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Sidlysp. z o.o. | $4,977,649.42 | sidly.eu | ||
| MedappS.A. | $3,351,163.61 | medapp.pl | ||
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | ||
| IntodnaS.A. | $2,286,118.76 | intodna.com | ||
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| Scope FluidicsS.A. | $1,264,188.85 | scopefluidics.com | ||
| Cardiomaticssp. z o.o. | $1,121,194.07 | cardiomatics.com | ||
| Saventic Healthsp. z o.o. | $1,089,246.05 | saventic.com | ||
| Active Textsp. z o.o. | $409,418.80 | active-text.pl | ||
| Digital Pathology Team Witold Reznersp. k. | $383,078.99 | digitalpathologyteam.com |
FAQ
Last updated: 2026-10-18